You have no items in your cart.
Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result
Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability ...
More from Ovarian Cancer News
-
-
Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer
Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin ... -
Pamiparib Granted Priority Review in China for Treatment of Advanced Ovarian Cancer
China’s regulatory agency has granted priority review status to BeiGene‘s new drug application (NDA) requesting ... -
PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer
China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved ... -
Small Inhibitor May Boost Effectiveness of PARP Inhibitors in Some Ovarian Cancers, Mouse Study Finds
A small inhibitor that prevents cells from making ribosomes — the machinery used to produce proteins ... -
Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial
The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not ... -
$2.2M Awarded to Collaboration Researching Rare Form of Ovarian Cancer
A research collaboration led by the Hudson Institute of Medical Research as been awarded a ... -
3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients
An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own ... -
FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice ... -
Second Surgery May Aid Survival in Recurrent Ovarian Cancer, Study Finds
Woman whose ovarian cancer returns more than six months after initial surgery and chemotherapy may benefit ... -
Groups Pledge Funding for Project to Develop Ovarian Cancer Blood Test
A team at Griffith University’s Institute for Glycomics in Australia has received $300,000 in funding from The ... -
Protein Biomarkers to Gauge Cancer Response to Chemo Identified
Investigators using targeted proteomics — a technique to detect proteins of interest — on samples of ... -
Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses
When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with ... -
DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show
A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in ... -
Zejula-Bevacizumab Combo Delays Progression in Relapsed Ovarian Cancer, Trial Finds
A combination of bevacizumab and Zejula (niraparib) is significantly better than Zejula alone at extending the ... -
More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows
VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women ... -
Genetic Testing for Breast, Ovarian Cancer Risk Safely Done at Home
Genetic tests to assess the risk of breast and ovarian cancer can be performed remotely ... -
Breastfeeding Lowers Risk of Ovarian Cancer for Decades, Study Finds
Women who breastfeed are at a significantly lower risk of developing ovarian cancer overall and ... -
Phase 2 Trial to Test Exercise as Way to Improve Quality of Life in Recurring Ovarian Cancer
A new Phase 2 clinical trial in Australia will assess whether exercise can improve the ... -
SOLO-2 Results: Maintenance Therapy with Lynparza Extends Survival in Relapsed Ovarian Cancer
Maintenance therapy with AstraZeneca’s Lynparza (olaparib) extended survival by more than one year in women ... -
Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial
Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease ... -
FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance ... -
STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show
STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women ... -
FDA Approves Zejula as First-line Maintenance Therapy for Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a first-line maintenance therapy for women ... -
Ovarian Cancer Often More Advanced at Diagnosis in Rural Areas in US
Women living in rural areas in the U.S. are significantly more likely to have metastatic ... -
Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say
While there are few silver linings to the cloud created by COVID-19, the pandemic that ... -
First Advanced Cancer Patients Dosed With VT1021 in Trial’s Expansion Phase
A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer ... -
Antibody-drug Conjugate XMT-1536 Shows Promise for Ovarian Cancer in Phase 1 Trial
Treatment with XMT-1536 appears to be safe, with promising responses shown in heavily pretreated patients ... -
Partnership to Ensure Gene-modified Cell Therapies for Ovarian Cancer Trials
Senti Biosciences is working with RoosterBio to ensure a quality supply of its candidate gene-modified cell therapies ... -
Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending
Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with ... -
GEN-1 Added to Chemo Improves Removal of Ovarian Tumors, Early Data Show
The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian ... -
Cellular Recycling Genes Linked to Ovarian Tumor Formation in Mice, Study Shows
Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of ... -
China Reviewing Zejula as First-line Therapy for Ovarian Cancer
The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) ...